ClinicalTrials.gg
Active, not recruitingNCT04995523ARTEMIDE-01Updated Nov 10, 2026

A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC

A Phase 1/2 interventional study of AZD2936 in Non-Small-Cell Lung Carcinoma, sponsored by AstraZeneca. Active, not recruiting at 40 sites in 16 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by AstraZeneca · Phase 1/2, Interventional, and Treatment

Updated Nov 10, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
212
Allocation
Non-randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 210 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca — 26 open to participants now, 79 under way, 28 of them phase 3. Carcinoma, Non-Small-Cell Lung · AstraZeneca.

Enrollment
53rd of 138
212 · median 153
Started
2021
with 13 others
Phase 1/2
10 of 210
2 open now
Primary completion
2028-06
later than 57 of 78 live
Registered
148th of 210
by date

Among the 210 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca, this one is the 53rd largest by enrollment of the 138 interventional ones that give a count, is one of 14 that started in 2021, is one of 10 in phase 1/2, reaches primary completion later than 57 of the 78 other live ones, and was the 148th registered.

Carcinoma, Non-Small-Cell Lung

7,632 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,839 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

26 of the 210 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

21 more — sign in →

By country, each count listing its studies:

All 26 open studies →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 210 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca, or all of them as a file.
02

Study summary

This is a Phase I/II study designed to evaluate if experimental anti-TIGIT/anti-PD-1 bispecific antibody rilvegostomig (AZD2936) is safe, tolerable and efficacious in participants with Advanced or Metastatic Non-small Cell Lung Cancer.

Read the detailed description

This is a first-time-in-human (FTIH), open-label, multicenter, multi-part, dose-escalation and dose-expansion study to evaluate the safety, pharmacokinetics (PK), pharmacodynamics, and efficacy of rilvegostomig (AZD2936) in adult participants with stage III unresectable or stage IV NSCLC. The study includes 4 parts: Part A (dose escalation) and Parts B-E (dose expansion).

03

Conditions studied

  • Non-Small-Cell Lung Carcinoma

Keywords

  • TIGIT, Anti-TIGIT
  • PD-1, Anti-PD-1
  • NSCLC, Non-small Cell Lung Cancer
  • Advanced, Metastatic, Solid Tumor, Solid Tumour
  • Stage 3 NSCLC, Stage III NSCLC
  • Stage 4 NSCLC, Stage IV NSCLC
  • PD L1+ tumors
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written
  • Aged 18 or above
  • Part A and Part B: Unresectable stage III or stage IV squamous or non-squamous NSCLC not amenable to curative surgery or radiation. Part C and Part D: Stage IV squamous or non-squamous NSCLC not amenable to curative surgery or radiation. Part E: Stage IV squamous NSCLC not amenable to curative surgery or radiation.
  • Documented expression by PD-L1 IHC per local report.
  • Part A and Part B: Confirmed progression during treatment with a CPI-including regimen.
  • Part C and Part D: No prior I/O treatment for NSCLC.
  • Part E: No prior treatment for metastatic NSCLC.
  • performance status of 0 or 1 at enrolment.
  • of ≥ 12 weeks at enrolment.
  • Have at least 1 per v1.1.
  • Adequate bone marrow, liver and kidney function

Exclusion criteria

Exclusion Criteria:

  • Sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) fusion
  • Documented test result for any other known genomic alteration for which a targeted therapy is approved in per local standard of care (e.g. ROS1, NTRK fusions, BRAF, V600E mutation)
  • Previous treatment with an anti-TIGIT therapy
  • Any concurrent chemotherapy, radiotherapy, , biologic, or hormonal therapy for cancer treatment.
  • Part A and Part B: Primary or secondary resistance after treatment with 2 or more regiments including a CPI.
  • Part C and Part D: Any prior systemic treatment with an immune oncology agent (prior administration of immune-oncology agent for curative intent to treat other invasive is permitted).

Treatment with one previous systemic chemotherapy will be allowed.

  • Part E: Any prior systemic treatment for NSCLC, including but not limited to chemotherapy, , anti-PD-L1, anti-CTLA-4.
  • Symptomatic central nervous system (CNS) metastasis.
  • Thromboembolic event within 3 months prior to enrolment.
  • Other invasive malignancy within 2 years prior to screening.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
212 participants (actual)

Study arms

  • Experimental
    Dose Escalation Part A: Checkpoint inhibitor (CPI) experienced Non-small Cell Lung Cancer (NSCLC)

    Rilvegostomig Intravenous (IV) monotherapy

    Drug: AZD2936

  • Experimental
    Dose Expansion Part B: CPI experienced NSCLC

    Rilvegostomig IV monotherapy

    Drug: AZD2936

  • Experimental
    Dose Expansion Part C: CPI Naive NSCLC

    Rilvegostomig IV monotherapy

    Drug: AZD2936

  • Experimental
    Dose Expansion Part D: CPI Naive NSCLC

    Rilvegostomig IV monotherapy

    Drug: AZD2936

  • Experimental
    Dose Expansion Part E: treatment Naive Squamous NSCLC

    Rilvegostomig IV monotherapy

    Drug: AZD2936

Interventions

  • Anti-TIGIT/Anti-PD-1 Bispecific Antibody

    Also known as: Rilvegostomig

06

What researchers measure

Primary outcomes

  1. Percentage of participants with adverse events (AEs) and immune mediated AEs (imAEs), serious AEs (SAEs), dose limiting toxicities (DLTs), vital signs, and abnormal laboratory parameters

    A DLT is a toxicity defined by the study protocol that occurs from the first dose of study intervention up to the end of the DLT evaluation period that is assessed as clearly unrelated to the primary disease or intercurrent illness.

    Time frame: Part A, B, C, D and E: From the time of informed consent until 90 days after the last dose of rilvegostomig

  2. Rate of rilvegostomig discontinuation due to toxicity

    Percentage of participants with AEs leading to discontinuation of rilvegostomig

    Time frame: Part A, B, C, D and E: From first dose to the last dose of rilvegostomig (an average of 6 months)

  3. Objective Response Rate (ORR)

    Percentage of participants with a confirmed Complete Response (CR) or Partial Response (PR) according to RECIST v1.1

    Time frame: Part B, C, D and E: From first dose of rilvegostomig to progressive disease (PD) or death in the absence of disease progression (approximately 2 years)

Secondary outcomes

  1. ORR

    Percentage of participants with a confirmed CR or PR according to RECIST v1.1

    Time frame: Part A: From first dose of rilvegostomig to PD or death in the absence of disease progression (approximately 2 years).

  2. Disease control rate (DCR)

    Percentage of participants who have a best objective response of confirmed CR or PR or who have SD lasting for at least a certain time of period after start of treatment

    Time frame: Part A, B, C, E: From first dose of rilvegostomig to PD or death in the absence of disease progression (approximately 2 years). Part D: From randomization to PD or death in the absence of disease progression (approximately 2 years).

  3. Duration of response (DoR)

    The time from first response according to RECIST v1.1 until progression or death in the absence of disease progression

    Time frame: Part A, B, C, D and E: From first dose of rilvegostomig to PD or death in the absence of disease progression (approximately 2 years).

  4. Durable response rate (DRR)

    The percentage of participants according to RECIST v1.1 with a confirmed CR or PR lasting 6 months or more

    Time frame: Part A, B, C, D and E: From first dose of rilvegostomig to PD or death in the absence of disease progression (approximately 2 years).

  5. Progression-free survival (PFS)

    The time from first dose of study intervention until the date of objective disease progression or death in the absence of disease progression

    Time frame: Part B, C, E: From first dose of rilvegostomig to PD or death in the absence of disease progression (approximately 2 years). Part D: From randomization to PD or death in the absence of disease progression (approximately 2 years).

  6. Measure the receptor occupancy (RO) of TIGIT and PD-1 on peripheral blood

    Evaluation of the target engagement of rilvegostomig in peripheral blood

    Time frame: Part A, B: From first dose of study intervention, at predefined intervals throughout the administration of rilvegostomig (approximately 2 years). The predefined intervals for Part A will be different from Part B.

  7. PK of rilvegostomig: Maximum plasma concentration of the study drug (Cmax)

    Maximum observed plasma concentration of rilvegostomig

    Time frame: From first dose of study intervention, at predefined intervals throughout the administration of rilvegostomig (approximately 2 years). The predefined intervals for Part A will be different from Part B, C, D and E.

  8. PK of rilvegostomig: Area under the concentration-time curve (AUC)

    Area under the plasma concentration-time curve

    Time frame: From first dose of study intervention, at predefined intervals throughout the administration of rilvegostomig (approximately 2 years). The predefined intervals for Part A will be different from Part B, C, D and E.

  9. PK of rilvegostomig: Clearance

    A pharmacokinetic measurement of the volume of plasma from which the study intervention is completely removed per unit time.

    Time frame: From first dose of study intervention, at predefined intervals throughout the administration of rilvegostomig (approximately 2 years). The predefined intervals for Part A will be different from Part B, C, D and E.

  10. PK of rilvegostomig: Terminal elimination half-life (t 1/2)

    Terminal elimination half life

    Time frame: From first dose of study intervention, at predefined intervals throughout the administration of rilvegostomig (approximately 2 years). The predefined intervals for Part A will be different from Part B, C, D and E.

  11. Incidence of anti-drug antibodies (ADA) against rilvegostomig in serum

    Immunogenicity of rilvegostomig

    Time frame: From first dose of study intervention, at predefined intervals throughout the administration of rilvegostomig (approximately 2 years). The predefined intervals for Part A will be different from Part B, C, D and E.

07

Study locations

40 sites
  • Research Site
    Chicago, Illinois 60637, United States
  • Research Site
    Rochester, Minnesota 55905, United States
  • Research Site
    Fairfax, Virginia 22031, United States
  • Research Site
    Melbourne, 3000, Australia
  • Research Site
    Anderlecht, 1070, Belgium
  • Research Site
    Leuven, 3000, Belgium
  • Research Site
    Florianópolis, 88034-000, Brazil
  • Research Site
    Natal, 59075-740, Brazil
  • Research Site
    Porto Alegre, 90035903, Brazil
  • Research Site
    Rio de Janeiro, 20231-050, Brazil
  • Research Site
    São Paulo, 01246-000, Brazil
  • Research Site
    Chengdu, 610041, China
  • Research Site
    Chongqing, 400030, China
  • Research Site
    Copenhagen, 2100, Denmark
  • Research Site
    Dijon, 21079, France
  • Research Site
    Toulouse, 31059, France
  • Research Site
    Tbilisi, 0112, Georgia
  • Research Site
    Kashiwa, 227-8577, Japan
  • Research Site
    Niigata, 951-8566, Japan
  • Research Site
    Sendai, 981-0914, Japan
  • Research Site
    Tokyo, 104-0045, Japan
  • Research Site
    Kuala Lumpur, 59100, Malaysia
  • Research Site
    Kuching, 93586, Malaysia
  • Research Site
    Chisinau, MD-2025, Moldova
  • Research Site
    Groningen, 9713 GZ, Netherlands
  • Research Site
    Leiden, 2333 ZA, Netherlands
  • Research Site
    Utrecht, 3584 CX, Netherlands
  • Research Site
    Seoul, 03082, South Korea
  • Research Site
    Seoul, 03722, South Korea
  • Research Site
    Seoul, 05505, South Korea
  • Research Site
    Barcelona, 08035, Spain
  • Research Site
    Madrid, 28027, Spain
  • Research Site
    Madrid, 28041, Spain
  • Research Site
    Taichung, 40201, Taiwan
  • Research Site
    Taichung, 40705, Taiwan
  • Research Site
    Tainan, 70403, Taiwan
  • Research Site
    Taipei, 110, Taiwan
  • Research Site
    Bangkok, 10700, Thailand
  • Research Site
    Chanthaburi, 22000, Thailand
  • Research Site
    Muang, 50200, Thailand
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level datain an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access.For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2021 (actual). Primary completion is estimated for Jun 2028, 80 months after the start.

Of 311 industry-sponsored phase 1/2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 77. This study's planned 80 months is above that.

Counting every sponsor, half of 434 studies reached it within 62 months; a quarter within 41 and three quarters within 80.

Primary completion moved once since we started tracking on Sep 25, 2026: Aug 2026 → Jun 2028, on Nov 10, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2021
First posted
Aug 9, 2021
StartActual
Sep 14, 2021
Primary completionEst.
Jun 1, 2028was Aug 2026
CompletionEst.
Jun 1, 2028
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Aug 28, 2026→Jun 1, 2028
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Primary completion Aug 28, 2026→Jun 1, 2028
    + 3 other changes: identifiers, verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04995523
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Aug 9, 2021
Start date
Sep 14, 2021
Primary completion
Jun 1, 2028 (estimated)
Completion
Jun 1, 2028 (estimated)
Last update
Nov 10, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rilvegostomig

Start the discussion